New Study Links Popular Diabetes Drugs to Lower Risk of Age-Related Vision Loss

A large new study suggests that a popular class of diabetes and weight-loss drugs may also protect against a leading cause of blindness in older adults. The findings add to a growing body of evidence that these medications could have benefits far beyond blood sugar control.

Patients who took glucagon-like peptide-1 receptor agonists (GLP-1RAs) — the same class of drugs as Ozempic, Wegovy, and Mounjaro — had a significantly lower chance of developing age-related macular degeneration (AMD) compared with patients taking other diabetes medications or cholesterol-lowering drugs, according to research published in the journal Ophthalmology Retina.

AMD is a progressive eye disease that damages the macula, the part of the retina responsible for sharp, central vision. It is the leading cause of severe vision loss in people over 60 in the United States. As the population ages, finding new ways to prevent or slow the disease has become a major public health priority.

What the Study Found

Researchers led by Dr. Aleksandra V. Rachitskaya of the Cleveland Clinic analyzed patient records from a large health database called TriNetX, covering the years 2005 to 2024. They focused on patients over 60 who had seen an eye doctor and were taking one of three types of medication: GLP-1 drugs, other glucose-lowering medications, or lipid-lowering drugs (like statins).

After carefully matching patients by health factors to make fair comparisons, the results were striking:

– For non-neovascular (dry) AMD: Patients on GLP-1 drugs had a 21% to 25% lower risk of developing the disease over three years compared with those on other diabetes medications.

– For neovascular (wet) AMD: The reduction was even larger — between 35% and 50% lower risk compared with other glucose-lowering drugs.

– Compared with lipid-lowering drugs: GLP-1 users had a 16% to 20% lower risk of dry AMD over two to three years, and a 30% to 40% lower risk of wet AMD.

– Important finding: The drugs did not appear to speed up the conversion from dry AMD to the more aggressive wet form, which some earlier reports had suggested.

The cumulative incidence numbers tell the story clearly. Among GLP-1 users, the chance of developing dry AMD rose from about 0.5% after one year to about 1.25% after three years. In comparison, patients on other diabetes drugs reached over 1.5% at three years. For wet AMD, GLP-1 users stayed below 0.5% at three years, while other diabetes drug users reached nearly 1%.

How This Affects You

For the millions of Americans taking GLP-1 drugs for diabetes or weight loss, these findings offer a potential added benefit. AMD affects about 11 million people in the United States, and that number is expected to grow as the population ages. Currently, there is no cure for AMD, and treatments for the wet form are expensive and require frequent eye injections.

If future studies confirm these results, GLP-1 drugs could become a new tool in the fight against vision loss. For older adults with diabetes — who are already at higher risk for eye disease — this could be particularly good news. However, experts caution that these medications are not yet proven to prevent AMD, and no one should start taking them solely for eye health.

What Experts Say About the Findings

While the results are promising, several independent experts urge caution. Dr. Rudrani Banik, an ophthalmologist at the Icahn School of Medicine at Mount Sinai who was not involved in the study, told MedPage Today that the effects seen are likely indirect.

“I think that the effects we’re seeing in these studies are indirect. And until we have prospective trials, we really can’t say this is a first-line or even second-line treatment strategy,” Banik said. “It’s promising, for sure, but I think it’s way too early to say ‘This drug is going to help’ reduce risk of AMD.”

Dr. Sarah DeParis, director of quality and clinical standards for the American Academy of Ophthalmology, echoed this caution. She noted that this type of study can find associations but cannot prove cause and effect.

“There can be differences between the groups of patients in the study that aren’t fully accounted for, which may influence the results,” DeParis said. She also pointed out that databases like TriNetX have limitations, including a lack of detailed eye imaging and visual acuity data, and they often miss patients treated in private ophthalmology practices.

Why GLP-1 Drugs Might Help the Eyes

GLP-1 receptor agonists work by mimicking a natural hormone that helps regulate blood sugar and appetite. But researchers have discovered they do much more. These drugs have already been shown to protect the heart and kidneys in people with diabetes and obesity.

The study authors explain that GLP-1 drugs affect insulin signaling and neurohormonal pathways in the body. They also appear to have anti-inflammatory and antioxidant properties. In the eye specifically, laboratory studies have shown that these medications can protect retinal ganglion cells — the nerve cells that send visual signals to the brain — from damage caused by high pressure and diabetes.

Previous research has suggested a protective role for GLP-1 drugs in glaucoma, another leading cause of blindness. However, studies on AMD have produced mixed results, leaving the issue uncertain until now.

How the Study Was Done

The researchers searched the TriNetX database for patients over 60 who had taken GLP-1 drugs, other diabetes medications, or cholesterol-lowering drugs between 2005 and 2024. Each patient had at least one documented eye exam. The investigators used diagnostic codes to determine whether patients developed dry or wet AMD at one, two, and three years after starting their medication.

In the first year of comparison, the GLP-1 group and the other diabetes drug group each had 43,532 patients. For the comparison with lipid-lowering drugs, each group had 42,464 patients. This large sample size gives the study strong statistical power.

Limitations to Keep in Mind

The study authors acknowledged several important limitations. They could not compare results for each eye separately, match patients by the severity or duration of existing AMD, or control for drug dosage or how consistently patients took their medication. Additionally, because this was a retrospective study — looking back at existing records — it cannot prove that the drugs directly caused the lower risk.

Practical Takeaways for Readers

– If you take a GLP-1 drug for diabetes or weight loss: These findings are encouraging but not a guarantee of eye protection. Continue your regular eye exams as recommended by your doctor.

– If you are at risk for AMD (over 60, family history, smoker): Talk to your eye doctor about your overall health and any medications you take. Do not start a GLP-1 drug solely for eye health.

– For everyone: The best ways to protect your vision include not smoking, eating a diet rich in leafy greens and omega-3 fatty acids, controlling blood pressure and cholesterol, and getting comprehensive dilated eye exams at least every two years after age 60.

– Stay tuned: The authors call for prospective clinical trials to confirm these findings. Such studies are the gold standard for determining whether a treatment truly works.

The study was published in Ophthalmology Retina and adds to the growing evidence that GLP-1 receptor agonists may have wide-ranging health benefits. But as Dr. Banik emphasized, the verdict is not yet in. For now, the best advice remains the same: manage your overall health, see your eye doctor regularly, and follow evidence-based recommendations for preventing vision loss.

Source: MedPage Today